Table 2 shows the probability of screening being cost effective at different cost effectiveness thresholds under the six different scenarios for the effect of screening on breast cancer incidence.
Modeling allows for exploration of cost-effectiveness of the program under study in different scenarios, e.g. to model cost-effectiveness under different assumptions regarding the duration of the treatment effect.
Interpreting the results of cost effectiveness analyses under uncertainty requires decision makers to think beyond conventional error rates as used in statistical analysis.
Figure 3 shows the incremental cost effectiveness ratio under the base case scenario for time horizons from 20 to 50 years.
We investigated the sample size requirement of this approach and the cost-effectiveness under different scenarios.
Such applications may be particularly important to maximize cost-effectiveness under the Accountable Care Organization model.
The purpose of this study is to calculate tiotropium's cost-effectiveness under real-world conditions.
The probabilities of cost-effectiveness under the $38,376 threshold were 99.7%, 99.5%, 100.0% and 89.5%, respectively.
In addition, a comprehensive cost effectiveness analysis is under way.
Positive values of incremental cost effectiveness mean that under MC complications are prevented compared to VCD; a positive signal thus represents a more favorable outcome of MC compared to VCD.> -wrap-foot> incrementalental cost effectiveness ratio, prev.
